News

Today, the U.S. Food and Drug Administration approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of…
Read More...

Novartis announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Enerzair…
Read More...

Arcturus Therapeutics Holdings Inc. and Catalent, Inc. announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended…
Read More...

Acceleron Pharma Inc. announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary…
Read More...

Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s proprietary DuckCelt-T17 cell line. The terms of the…
Read More...

Junshi Biosciences and Eli Lilly and Company announced they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19,…
Read More...

Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development…
Read More...

INOVIO announced it has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support…
Read More...

Moderna, Inc. a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and…
Read More...

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at…
Read More...

WuXi Biologics and Aravive, Inc. announced a strategic collaboration agreement granting Aravive the right to use the proprietary WuXiBody platform to develop high-affinity bispecific…
Read More...

Trio Pharmaceuticals, Inc. ("TRIO"), a cancer therapeutics company developing novel dual action antibody drugs, TRIObody, and novel dual action antibody drug conjugates, TRIObody Drug…
Read More...

Novartis announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing…
Read More...

BioDuro, LLC, a leading drug discovery and development services organization, and neoX, a leading-edge artificial intelligence and biophysics focused biotech, announced a strategic…
Read More...

The University of Queensland’s COVID-19 vaccine has passed another important milestone, showing the ability to raise high levels of antibodies that can neutralise the virus in early…
Read More...

Gilead Sciences, Inc. announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in…
Read More...

Atreca, Inc. BeiGene, Ltd. and IGM Biosciences, Inc. announced their plans to collaborate to help address the COVID-19 pandemic. The companies will leverage their combined technology…
Read More...

GlaxoSmithKline plc announced the US Food and Drug Administration (FDA) approved the company’s supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly…
Read More...

Catalent, Inc. announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of…
Read More...

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced by Quotient Sciences and CytoAgents, Inc. The partnership will…
Read More...